Gestational Diabetes

Gestational diabetes mellitus is glucose intolerance first recognized during pregnancy in a person not previously known to have diabetes. It arises when the insulin resistance that normally develops in pregnancy outstrips maternal insulin secretion, and it is associated with increased risks of fetal overgrowth, neonatal complications, and later maternal type 2 diabetes.

Definition

Gestational diabetes mellitus is carbohydrate intolerance of variable severity with onset or first recognition during pregnancy, reflecting an inability of maternal insulin secretion to compensate for the insulin resistance of pregnancy.

Scope

This entry covers the definition and physiology of gestational diabetes, the rationale for screening and the diagnostic frameworks used, the spectrum of associated maternal and perinatal outcomes, and the evidence that treatment improves those outcomes. It is a reference and educational overview; it does not provide glucose targets, dosing, or any individualized management instruction.

Core questions

• Why does pregnancy promote insulin resistance, and when does it lead to gestational diabetes?
• How is gestational diabetes screened for and diagnosed, and why are diagnostic criteria contested?
• What maternal and perinatal outcomes are associated with maternal hyperglycemia?
• Does treating gestational diabetes improve pregnancy outcomes?

Key concepts

• Pregnancy-induced insulin resistance
• Maternal hyperglycemia
• Glucose screening and oral glucose tolerance test
• IADPSG diagnostic criteria
• Macrosomia and large-for-gestational-age infants
• Neonatal hypoglycemia
• Continuum of hyperglycemia and outcome risk
• Future maternal type 2 diabetes risk

Mechanisms

Pregnancy is a physiologically insulin-resistant state: placental hormones and increased maternal adiposity reduce insulin sensitivity, normally offset by a compensatory rise in insulin secretion. Gestational diabetes develops when beta-cell compensation is insufficient, so maternal glucose rises. Because glucose crosses the placenta freely while insulin does not, maternal hyperglycemia drives fetal hyperinsulinemia, which promotes fetal growth and adiposity and predisposes the newborn to hypoglycemia after birth (Reece, 2009). The HAPO study demonstrated that the relationship between maternal glucose and adverse outcomes is continuous, with no clear threshold (HAPO Study Cooperative Research Group, 2008).

Clinical relevance

Gestational diabetes is one of the conditions for which antenatal screening is widely employed, and recognition of its associated risks informs maternal and neonatal surveillance. Randomized trials show that identifying and treating the condition can reduce certain adverse outcomes (Crowther, 2005; Landon, 2009). This entry explains why the condition matters and how it is framed; it is not a basis for individual diagnosis or treatment, which rest with the responsible clinician.

Epidemiology

Prevalence estimates vary widely with the population studied and the diagnostic criteria applied, and have risen with increasing maternal age and obesity. Risk factors include obesity, prior gestational diabetes, a family history of type 2 diabetes, certain ethnic backgrounds, and prior macrosomic birth; affected individuals carry a substantially elevated lifetime risk of type 2 diabetes (Reece, 2009).

Evidence & guidelines

The HAPO cohort established the continuous glucose-outcome relationship (HAPO Study Cooperative Research Group, 2008), which the IADPSG consensus used to derive diagnostic thresholds (IADPSG, 2010). Two landmark randomized trials, the ACHOIS trial (Crowther, 2005) and the NICHD mild-GDM trial (Landon, 2009), demonstrated that treatment reduces specific perinatal harms, providing the evidence base for active management.

History

Glucose intolerance in pregnancy was systematically studied from the mid-twentieth century, with O'Sullivan and Mahan establishing early screening criteria based on future maternal diabetes risk. Subsequent decades saw debate over whether and how to diagnose milder hyperglycemia. The HAPO study (2008) reframed the field by showing a continuous risk gradient, and the IADPSG (2010) translated those data into diagnostic criteria, while randomized trials clarified the benefits of treatment.

Debates

What diagnostic thresholds should define gestational diabetes?

Because the HAPO data show a continuous relationship between glucose and outcomes, where to set diagnostic cut-points is a value judgment; the IADPSG criteria broadened diagnosis, and the optimal thresholds and one- versus two-step screening remain debated.

Key figures

• Boyd Metzger
• John B. O'Sullivan

Seminal works

• hapo-2008
• iadpsg-2010
• crowther-2005
• landon-2009

Frequently asked questions

Why does pregnancy increase the risk of high blood sugar?

Pregnancy is normally a state of increased insulin resistance driven by placental hormones; gestational diabetes occurs when maternal insulin secretion cannot rise enough to keep glucose in the normal range.

Does treating gestational diabetes actually help?

Randomized trials, including the ACHOIS trial (Crowther, 2005) and the NICHD mild-GDM trial (Landon, 2009), found that treating gestational diabetes reduced certain adverse perinatal outcomes compared with no specific treatment.